.jpeg)
{{ variable.name }}
Infigratinib is a fibroblast growth factor receptor (FGFR)-specific tyrosine kinase inhibitor.
1. Generic name: Infigratinib (Infigratinib)
2. Trade name: TRUSEL TIQ
It is used to treat adult patients who have been detected to have FGFR2 gene fusion or rearrangement. It is suitable for locally advanced or metastatic cholangiocarcinoma that has been previously treated and cannot be surgically removed. This indication received accelerated approval based on overall response rate and duration of response.
100mg, capsule
1. Active ingredient: Infigratinib phosphate
2. Excipients: Colloidal silicon dioxide, crospovidone, hypromellose, etc.
1. Standard dose of : 125mg (1 pill of 100mg + 1 pill of 25mg) once a day, take it continuously for 21 days and then stop taking it for 7 days, and 28 days is a cycle.
2. How to take : Take it on an empty stomach (1 hour before a meal or 2 hours after a meal). Swallow the whole tablet without crushing or chewing.
3. Treatment of missed doses : If you miss a dose for more than 4 hours or vomit, take the medicine as originally planned the next day, and there is no need to make up for it.
1. Renal insufficiency : Adjust to 100 mg once a day for patients with mild to moderate renal insufficiency.
2. Hepatic insufficiency : Adjust to 100mg once a day for mild, and 75mg once a day for moderate.
3. Adverse reaction adjustment : Dose suspension, reduction or permanent discontinuation according to toxicity classification (phosphate binders need to be adjusted if hyperphosphatemia).
1. Dietary influence : Avoid taking it with grapefruit products; it should be taken at intervals between taking it and acid-suppressing drugs (H2 receptor antagonists should be taken 2 hours apart, and antacids should be taken 2 hours apart).
2. Eye monitoring : Regular eye examinations are required before and during treatment to be alert for retinal pigment epithelial detachment (RPED).
3. Management of hyperphosphatemia : Serum phosphorus levels need to be monitored and phosphate binders used if necessary.
1. Pregnancy/breastfeeding : can cause fetal damage. Contraception is required during medication and within 1 month of stopping the medication; it is contraindicated during lactation.
2. Children : Safety has not been established.
3. Elderly : No need to adjust the dose.
1. Common (≥20%) include:nail toxicity, stomatitis, dry eye syndrome, fatigue, alopecia, hand-foot syndrome, etc.;
2. Laboratory abnormalities include:increased serum creatinine, hypophosphatemia, elevated ALT, etc.
There are no clear contraindications.
1. CYP3A inhibitor/inducer : Avoid combined use with strong/moderate CYP3A inhibitors (such as itraconazole) or inducers (such as rifampicin).
2. Gastric acid regulator : Avoid using it in combination with PPI, and adjust the taking time of H2 antagonists or antacids if necessary.
Save at 20°C-25°C, allowing short-term fluctuations of 15°C-30°C.